CA2129987A1 - Inhibition de l'adhesion des cellules par des oligosaccharides chimiquement definis, leurs derives et mimetiques, et anticorps diriges vers ceux-ci - Google Patents

Inhibition de l'adhesion des cellules par des oligosaccharides chimiquement definis, leurs derives et mimetiques, et anticorps diriges vers ceux-ci

Info

Publication number
CA2129987A1
CA2129987A1 CA002129987A CA2129987A CA2129987A1 CA 2129987 A1 CA2129987 A1 CA 2129987A1 CA 002129987 A CA002129987 A CA 002129987A CA 2129987 A CA2129987 A CA 2129987A CA 2129987 A1 CA2129987 A1 CA 2129987A1
Authority
CA
Canada
Prior art keywords
carbohydrate
cells
antibody
lex
elam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002129987A
Other languages
English (en)
Inventor
Naoya Kojima
Kazuko Handa
Sen-Itiroh Hakomori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomembrane Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2129987A1 publication Critical patent/CA2129987A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002129987A 1992-02-19 1993-02-19 Inhibition de l'adhesion des cellules par des oligosaccharides chimiquement definis, leurs derives et mimetiques, et anticorps diriges vers ceux-ci Abandoned CA2129987A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US83697892A 1992-02-19 1992-02-19
US07/836,978 1992-02-19
US95072092A 1992-09-25 1992-09-25
US07/950,720 1992-09-25
US99690392A 1992-12-29 1992-12-29
US07/996,903 1992-12-29

Publications (1)

Publication Number Publication Date
CA2129987A1 true CA2129987A1 (fr) 1993-09-02

Family

ID=27420263

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002129987A Abandoned CA2129987A1 (fr) 1992-02-19 1993-02-19 Inhibition de l'adhesion des cellules par des oligosaccharides chimiquement definis, leurs derives et mimetiques, et anticorps diriges vers ceux-ci

Country Status (4)

Country Link
EP (1) EP0638085A1 (fr)
JP (1) JPH07504222A (fr)
CA (1) CA2129987A1 (fr)
WO (1) WO1993017033A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2227013A1 (fr) * 1995-07-14 1997-02-06 Glycotech Corp. Composes et methodes de traitement de cancers lies au recepteur egf et purification du recepteur egf
AUPP913999A0 (en) * 1999-03-12 1999-04-01 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
DE19930177B4 (de) 1999-06-30 2007-02-08 Nikolai Vladimirovich Bovin Intermolekular assoziierende Verbindungen und deren Verwendung
DE10056136A1 (de) * 2000-11-07 2002-05-16 Nemod New Modalities Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen
US7374906B2 (en) 2000-11-08 2008-05-20 Surface Logix, Inc. Biological assays using gradients formed in microfluidic systems
US7326563B2 (en) 2000-11-08 2008-02-05 Surface Logix, Inc. Device and method for monitoring leukocyte migration
FI20011664A (fi) 2001-08-17 2003-02-18 Carbion Oy Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
JP5331293B2 (ja) * 2006-04-28 2013-10-30 公益財団法人野口研究所 多様性を表現するオリゴ糖またはその誘導体
JP5894732B2 (ja) * 2010-11-11 2016-03-30 学校法人東京女子医科大学 細胞培養基材の評価方法

Also Published As

Publication number Publication date
EP0638085A1 (fr) 1995-02-15
JPH07504222A (ja) 1995-05-11
WO1993017033A1 (fr) 1993-09-02

Similar Documents

Publication Publication Date Title
Smith et al. The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
Fukuda Possible roles of tumor-associated carbohydrate antigens
Fraschilla et al. Viewing Siglecs through the lens of tumor immunology
Takano et al. Sialylation and malignant potential in tumour cell glycosylation mutants
Crocker et al. Purification and properties of sialoadhesin, a sialic acid‐binding receptor of murine tissue macrophages.
Marathe et al. Fluorinated per-acetylated GalNAc metabolically alters glycan structures on leukocyte PSGL-1 and reduces cell binding to selectins
US5648344A (en) Methods of treating inflammation using selection binding compounds
Ohyama et al. Dual roles of sialyl Lewis X oligosaccharides in tumor metastasis and rejection by natural killer cells
US5211937A (en) Method of determining a site of inflammation utilizing elam-1 ligands
Mannori et al. Inhibition of colon carcinoma cell lung colony formation by a soluble form of E-selectin.
US5876715A (en) Antibodies that bind novel carbohydrate ligands (myelorollins) that cause E-selectin dependent cell rolling, and uses thereof
US20030133937A1 (en) Methods and compositions for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
IE913722A1 (en) Agents and methods for binding to elam-1
Lloyd et al. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells
Lefebvre et al. Altered glycosylation of leukosialin, CD43, in HIV-1-infected cells of the CEM line.
WO1992018610A2 (fr) Compositions et procedes de liaison endotheliale
Cook Cell surface carbohydrates: molecules in search of a function?
CA2129987A1 (fr) Inhibition de l'adhesion des cellules par des oligosaccharides chimiquement definis, leurs derives et mimetiques, et anticorps diriges vers ceux-ci
JPH06508823A (ja) ２，６シアル酸成分を含むインヒビターによるｐａｄｇｅｍ媒介相互作用の阻害方法
Watarai et al. Production of monoclonal antibodies directed to Hanganutziu-Deicher active gangliosides, N-glycolylneuraminic acid-containing gangliosides
Pinola et al. Characterization of the E-selectin ligand on NK cells.
AU659808B2 (en) Inhibition of metastasis potential and invasiveness by oligosaccharides or oligosaccharide antigens or antibodies
Stanford et al. The role of tumor‐cell surface carbohydrate in experimental metastasis
EP0521692A2 (fr) Inhibition de la potentiel métastasique et l'énvahissement par oligosaccharides ou ses conjugés
EP0765884B1 (fr) Composés anti-inflammatoires

Legal Events

Date Code Title Description
FZDE Dead